• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by CNS Pharmaceuticals Inc.

    8/14/25 8:56:25 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNSP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    CNS PHARMACEUTICALS INC

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    09057N409

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    09057N409


    1Names of Reporting Persons

    Armistice Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    561,148.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    561,148.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    561,148.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    09057N409


    1Names of Reporting Persons

    Steven Boyd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    561,148.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    561,148.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    561,148.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CNS PHARMACEUTICALS INC
    (b)Address of issuer's principal executive offices:

    2100 WEST LOOP SOUTH, SUITE 900, HOUSTON, TX, 77027
    Item 2. 
    (a)Name of person filing:

    Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
    (b)Address or principal business office or, if none, residence:

    Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
    (c)Citizenship:

    Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    09057N409
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    561,148
    (b)Percent of class:

    9.99  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    561,148

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    561,148 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Armistice Capital, LLC
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd - Managing Member
    Date:08/14/2025
     
    Steven Boyd
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd
    Date:08/14/2025
    Exhibit Information

    JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

    Get the next $CNSP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNSP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CNSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brookline Capital initiated coverage on CNS Pharmaceuticals with a new price target

    Brookline Capital initiated coverage of CNS Pharmaceuticals with a rating of Buy and set a new price target of $10.00

    2/2/21 10:31:34 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gumulka Jerzy bought $10,000 worth of shares (33,333 units at $0.30), increasing direct ownership by 345% to 43,006 units (SEC Form 4)

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    2/6/24 10:28:10 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evans Carl Anthony bought $10,000 worth of shares (33,333 units at $0.30), increasing direct ownership by 26,666% to 33,458 units (SEC Form 4)

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    2/6/24 10:27:56 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Downs Christopher bought $20,000 worth of shares (66,666 units at $0.30), increasing direct ownership by 181% to 103,438 units (SEC Form 4)

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    2/6/24 10:27:39 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by CNS Pharmaceuticals Inc.

    SCHEDULE 13G - CNS Pharmaceuticals, Inc. (0001729427) (Subject)

    8/14/25 8:56:25 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CNS Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    7/22/25 4:39:58 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CNS Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    7/15/25 5:19:52 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Cortice Biosciences, Inc.

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    8/6/24 5:11:50 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Cortice Biosciences, Inc. claimed ownership of 573,368 shares (SEC Form 3)

    3 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    8/6/24 4:53:41 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mahery Amy

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    4/10/24 9:53:15 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

    Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion LeadersCompany committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cureRegister for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET.For the event, John Climaco, C

    12/5/24 9:10:00 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

    Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 HOUSTON, TX / ACCESSWIRE / November 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier

    11/25/24 9:00:00 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

    HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX.Details of the presentation are as follows:Title:Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs. Lomustine After First-Line Therapy for Glioblastoma Multiforme (GBM)Presenter: Sandra Silberman, MD, Ph

    11/18/24 8:56:05 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    Leadership Updates

    Live Leadership Updates

    View All

    Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

    Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and immunologyHOUSTON, TX / ACCESSWIRE / January 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has appointed Amy Mahery to its Board of Directors, effective upon completion of a financing. Ms. Mahery, who currently serves as the Chief Commercial Officer of Roivant Sciences, a $9 Billion market cap b

    1/18/24 8:45:00 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors

    Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations HOUSTON, Jan. 3, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has appointed Faith L. Charles as Chair of its Board of Directors. "The depth and breadth of knowledge, experience and network that Fait

    1/3/23 12:00:00 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esports Technologies Adds Deep Expertise in Corporate Finance and Operations With Appointment of Christopher Downs to its Board of Directors

    LAS VEGAS, March 16, 2021 /PRNewswire/ -- Esports Technologies, Inc., a global provider of advanced esports wagering products, today announced the appointment of Christopher Downs to its Board of Directors, effective March 5, 2021. Downs will lend his years of corporate finance experience to Esports Technologies as it accelerates its growth in esports wagering. As a board member of Esports Technologies, Downs will chair the Audit Committee and serve on both the Compensation and Nominating and Governance Committees. Esports Technologies Adds Deep Expertise in Corporate Finance and Operations With Appointment of Christopher Downs to its Board of Directors Aaron Speach, Esp

    3/16/21 9:03:00 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CNS Pharmaceuticals Inc.

    SC 13G/A - CNS Pharmaceuticals, Inc. (0001729427) (Subject)

    11/14/24 3:58:53 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by CNS Pharmaceuticals Inc.

    SC 13D - CNS Pharmaceuticals, Inc. (0001729427) (Subject)

    8/2/24 4:11:48 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by CNS Pharmaceuticals Inc.

    SC 13G - CNS Pharmaceuticals, Inc. (0001729427) (Subject)

    7/2/24 12:34:25 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care